NCT04679870View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 9, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

June 30, 2026

Conditions
Myelofibrosis
Interventions
DRUG

GB2064

GB2064 (formerly PAT-1251) is a high-affinity, selective, mechanism-based, small molecule inhibitor of LOXL2, administered twice a day

Trial Locations (11)

2605

Woden Dermatology, Canberra

10043

Azienda Ospedaliero-Universitaria San Luigi Gonzaga di Orbassano, Orbassano

20162

ASST Grande Ospedale Metropolitano Niguarda, Milan

21100

Azienda Socio-Sanitaria Territoriale dei Sette Laghi, Varese

40138

University of Bologna Sant Orsola Malpighi, Bologna

40225

Heinrich-Heine-University Dusseldorf, Düsseldorf

50134

Azienda Ospedaliero-Universitaria Careggi, Florence

69120

Universitätsklinikum Heidelberg, Heidelberg

77030

MD Andersson Cancer Hospital, Houston

81675

Klinikum rechts der Isar der Technischen Universitaet Munchen, München

04103

Universität Leipzig, Leipzig

Sponsors

Lead Sponsor

Galecto Biotech AB
All Listed Sponsors
collaborator

OPIS s.r.l

UNKNOWN

lead

Galecto Biotech AB

INDUSTRY